University of California San Francisco
San Francisco, California, 94143, United States
NCT Number: NCT00611182
This study has two aims:
1. To determine the relationship of shortness of breath (dyspnea) to other conditions present in patients with pulmonary fibrosis. 2. To define the relationship between shortness of breath and rate of functional decline in patients with pulmonary fibrosis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
San Francisco, California, 94143, United States
Idiopathic Pulmonary Fibrosis is the most common form of chronic fibrosing lung disease seen by pulmonologists, with an estimated 128,000 cases in the United States alone. It is almost surely a disorder related to aging, with a median age at the time of diagnosis of approximately 65 years; IPF is almost unheard of under the age of 50. Dyspnea is common in patients with IPF, and is often the primary symptom of the disease. It is tightly linked to quality of life in IPF, suggesting that the experience of dyspnea has wide-ranging and clinically-significant consequences. Despite its importance, surprisingly little is known about the etiology or functional impact of dyspnea in this disease.
This research proposal focuses on defining the relationship of dyspnea to comorbidity and the rate of functional decline in patients with IPF
Aim 1: To determine the relationship of dyspnea to other conditions present in patients with IPF.
Dyspnea is a complex symptom, related to both mechanical and cognitive factors. The mechanisms of dyspnea in IPF remain unknown, but there are several likely contributors that are both IPF and non-IPF related. Although IPF is a chronic disease of the elderly, no one has investigated the relationship between common geriatric conditions and dyspnea. It is well established that the perception of dyspnea depends equally on factors that influence the intensity of the experience of breathlessness (such as thoracic restriction and weakness) and the distress which that intensity produces. Gender, ethnicity, anxiety, pain, and depression all may contribute to the distress caused by dyspnea (and therefore its intensity) in IPF.
Aim 2: To define the relationship between dyspnea and rate of functional decline in IPF.
Numerous studies have looked at predictors of survival in patients with IPF, and both baseline and change in dyspnea over time have been shown to be significantly associated. The prediction of future morbidity, however, is largely unstudied. Established markers of functional decline in geriatric patients include weight loss, decline in walking speed over 4 meters, and the onset of disability as defined by the ability to perform activities of daily living (ADLs) and instrumental activities of daily living (IADLs). Dyspnea likely impacts patients' activity levels and/or motivation to stay active, and may contribute to worsening functional decline.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Time frame: 6 months
University of California, San Francisco
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04170062
Chronic Disease, Disease Attributes
Baltimore, Maryland, United States
View Trial DetailsNCT04619680
COVID-19, Cicatrix
Atlanta, Georgia, United States
View Trial DetailsNCT04308681
Fibrosis, Idiopathic Interstitial Pneumonias
Birmingham, Alabama, United States
View Trial DetailsNCT03385668
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Autoimmune Diseases
Paris, France
View Trial Details